NICE technology appraisal guidance
Issued: December 2012
TA269

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta269

1 Guidance

1.1 Vemurafenib is recommended as an option for treating BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.